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Clinical review
Science, medicine, and the future
Radiofrequency ablation for atrial fibrillation
Neil R Grubb, Steve Furniss
Atrial fibrillation is a common arrhythmia, especially
among elderly people. Restoration of sinus rhythm by
cardioversion or drug treatment improves symptoms,
cardiac output, and exercise tolerance. Unfortunately,
the recurrence rate in successfully treated patients is
high. Research into the underlying electrophysiologi›
cal mechanisms that cause atrial fibrillation has fuelled
the development of new therapeutic approaches. This
article describes the advances in understanding how
the arrhythmia is generated and discusses the
therapeutic potential of radiofrequency ablation.
Methods
We obtained information from several sources. We
used Medline and BIDS to identify key papers, and we
searched abstracts from the meetings of the American
College of Cardiology, American Heart Association,
and North American Society of Pacing and Electro›
physiology between 1995 and 2000 for additional
information on evolving technologies.
Atrial fibrillation
The prevalence of atrial fibrillation in the adult
population is 0.5%, rising to 10% among people aged
over 75 years.1 It is associated with a 5›6 fold increase in
the incidence of stroke.2 A 70 year old person with
atrial fibrillation thus has an annual risk of stroke or
transient cerebral ischaemic attack of 5%.
Atrial fibrillation may be paroxysmal, persistent, or
permanent. Paroxysmal atrial fibrillation is character›
ised by repeated, self terminating episodes of arrhyth›
mia. This can progress to either persistent atrial
fibrillation, in which an intervention such as direct cur›
rent cardioversion may restore sinus rhythm, or
permanent atrial fibrillation, which is resistant to
cardioversion. Many patients with atrial fibrillation are
asymptomatic, especially if their heart rate is not rapid.
If symptoms do occur their severity is determined by
the underlying state of the heart and the patient’s heart
rate at rest and during exercise.
Restoration of sinus rhythm with direct current or
pharmacological cardioversion improves symptoms,
cardiac output, and exercise tolerance and is initially
successful in up to 90% of patients, but the rate of recur›
rence after a year can be as high as 60%.3 4 The risk of
recurrence is determined both by mechanical factors
(such as valve disease) and electrophysiological triggers
(such as atrial ectopy). As a result, considerable effort has
been directed at identifying the electrophysiological
mechanisms that cause atrial fibrillation and at new
therapeutic approaches that target these mechanisms.
Electrophysiological mechanisms that
cause atrial fibrillation
Atrial fibrillation is the result of both substrate and
trigger. The substrate is most often a pathology that
affects the atria, such as hypertensive heart disease
(associated with increased stress on the atrial wall).5
The trigger often consists of an ectopic atrial electrical
focus.6 Although this focus can arise anywhere in the
atria, left atrial foci at or within the pulmonary vein ori›
fices are often responsible for episodes of atrial fibrilla›
tion in patients with otherwise normal hearts.
Once initiated, the arrhythmia is maintained by the
mechanism of re›entry.7 Macro re›entry occurs when a
continuous loop of atrial depolarisation is set up
around an anatomical or functional conduction barrier
(such as a vein orifice or zone of diseased atrial tissue).
It occurs especially when conduction propagates in
only one direction around the barrier (fig 1). During
atrial fibrillation many such re›entry circuits are estab›
lished in the atria. These sustain themselves more
readily in diseased or enlarged atria.
Over time, the prospect of spontaneous return to
sinus rhythm diminishes because of maladaptive
changes that occur in atrial tissue. These include
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shortening of the refractory period of atrial myocytes,
which encourages macro re›entry because myocytes are
excitable for a greater proportion of each cycle (fig 1).
This process is known as electrical remodelling.8
Current management of atrial fibrillation
Current management focuses on two issues—
preventing stroke and treating the arrhythmia.
Guidelines for preventing stroke are published
elsewhere.9 Arrhythmia is managed by the sinus
rhythm strategy or the rate control strategy. The sinus
rhythm strategy strives to restore and maintain sinus
rhythm with cardioversion or antiarrhythmic drugs, or
both. Drugs such as sotalol, propafenone, and
amiodarone are used to preserve sinus rhythm, but
these can be proarrhythmic or may not be tolerated.
The rate control strategy accepts that atrial fibrilla›
tion is likely to persist and uses atrioventricular node
blocking drugs such as digoxin or â blockers to limit
the heart rate. The risk of stroke and some of the
haemodynamic consequences of atrial fibrillation per›
sist, and heart rate control can be difficult to achieve
both at rest and during exercise. The rate control
option tends to be used for patients with substantial
structural heart disease or when the sinus rhythm
strategy has failed. Despite their disadvantages, these
treatments provide satisfactory symptom control for
most patients with atrial fibrillation.
New non›pharmacological treatments
Atrial fibrillation can be treated with physical as well as
pharmacological interventions. Internal cardioversion
administered by catheter is effective in three quarters of
patients who are resistant to external cardioversion, but
it is still associated with a high recurrence rate.10 Atrial
pacing can prevent atrial fibrillation by inhibiting
ectopic activity and preventing excessive bradycardia.
Trials are in progress to evaluate pacemakers that detect
trends in heart rate and ectopy known to be associated
with paroxysms of atrial fibrillation and that initiate sin›
gle site or multisite pacing in response to these
changes.11 12 Implantable atrial defibrillators detect
episodes of atrial fibrillation at their onset and deliver an
internal direct current shock.13
Cardioversion is administered before electrical
remodelling occurs but can be unpleasant for the
patient. These devices are reserved for patients with
symptomatic, drug resistant, paroxysmal atrial fibrilla›
tion. For patients with persistent or permanent atrial
fibrillation, surgical techniques have been developed
that prevent re›entry by means of linear atrial incisions
that act as electrical barriers.14–16
Radiofrequency ablation
Except for atrial surgery, none of the above treatments
directly and permanently targets the trigger or substrate
for atrial fibrillation. There is therefore considerable
interest in recent developments in catheter ablation,
which target these mechanisms and which may offer a
cure for selected patients with this condition.
Radiofrequency ablation is the targeted cautery of
cardiac tissue by local application of radiofrequency
energy. Target zones are identified during an electro›
physiological study, in which a series of catheters are
placed in the heart (fig 2). Accessory pathways or other
critical parts of arrhythmia circuits are identified by
recording the cardiac electrical activation sequence.
Once a target zone is identified, ablation is performed by
heating the interface between catheter and endocar›
dium until cell death occurs, at temperatures over 47°C.
Ablation has become the treatment of choice for
most patients with supraventricular tachycardia due to
accessory pathways or to atrioventricular nodal
re›entry, and is becoming widely used for treating atrial
flutter.16 Until recently, ablation has had only a limited
role in treating atrial fibrillation itself, but better under›
standing of the mechanisms causing such arrhythmia
has stimulated the development of new ablation
techniques that target both substrate and trigger. The
role of ablation differs for each of the presentations of
atrial fibrillation.
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Fig 1 Electrical re›entry, the mechanism responsible for initiating and maintaining atrial
fibrillation
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Fig 2 Target sites for different radiofrequency ablation approaches in
treating atrial fibrillation: 1 pulmonary vein ectopic foci, 2 proximal
bundle of His, 3 atrial walls for linear ablation
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Paroxysmal atrial fibrillation
Some patients with self terminating paroxysms of atrial
fibrillation have their arrhythmia initiated by rapid
repetitive discharges from foci within one or more of
the pulmonary veins or, occasionally, the superior vena
cava.6 17–19 These structures contain sleeves of atrial tis›
sue that extend a variable distance from the atria
themselves. The culprit foci often lie several centime›
tres inside the vein, and spontaneous ectopic activity
arising therein propagates into the atria, initiating and
sometimes maintaining atrial fibrillation.
It is possible to locate these foci during an electro›
physiological study. As they are usually in the
pulmonary veins, the interatrial septum has to be
punctured to allow catheters to pass into the left atrium
and pulmonary veins from the right atrium. Radiofre›
quency ablation can be used either to destroy the
culprit foci or to isolate them electrically from the atria.
This technique is highly effective in the short term, but
initial reports suggest high recurrence rates, possibly
because of the occurrence of multiple foci in different
pulmonary veins or because of inadequate isolation of
culprit foci.19 The procedure may be complicated by
pulmonary vein stenosis, a potentially serious compli›
cation that can lead to pulmonary hypertension and
right sided cardiac failure. An early report cited a 5%
incidence of pulmonary vein stenosis, although
relatively high radiofrequency energies were used,
often in sites deep within the veins.19
New techniques are being evaluated with the goal
of achieving complete and rapid electrical isolation of
the pulmonary veins from adjacent atrial tissue. It is
possible that this anatomical approach will provide
better results than simply ablating in the region of the
foci themselves.
Persistent atrial fibrillation
Persistent atrial fibrillation usually affects patients with
structural or ischaemic heart disease. Atrial disease
tends to maintain atrial fibrillation once it occurs. Sinus
rhythm can be restored with electrical or pharmacologi›
cal cardioversion, but fibrillation tends to recur because
of the persistence of triggering foci and underlying atrial
disease. Focal ablation in this setting is less successful for
the above reasons and possibly because of the presence
of multiple triggering foci within the atria and
pulmonary veins. Hybrid ablation strategies that target
both the trigger, through focal ablation, and the
substrate, by linear ablation and compartmentalisation
(see below), are under development.20
Although restoration of sinus rhythm is the goal for
these patients, it cannot always be achieved or
sustained. In resistant cases ablation can be used to
control heart rate in patients who develop an inappro›
priate tachycardia during exercise or for whom drugs
are ineffective or have unacceptable side effects. The
region of the compact atrioventricular node or His
bundle is ablated to achieve complete atrioventricular
block; a permanent pacemaker is then implanted to
control heart rate.21–23 This is known as the “ablate and
pace” strategy. Modern pacemakers are capable of
increasing the ventricular rate appropriately in
response to exercise during atrial fibrillation. In
patients with paroxysmal atrial fibrillation a mode
switching pacemaker is used, which, as well as control›
ling the heart rate during paroxysms, maintains
synchrony of atrial and ventricular contraction during
sinus rhythm. Regularising the ventricular rhythm dur›
ing atrial fibrillation also improves symptoms and
haemodynamic performance.21 22 Concerns have been
expressed about an association between total atrioven›
tricular nodal ablation and death due to bradycardia›
related torsades de pointes ventricular tachycardia.
This risk can be virtually eliminated with pacing at
80›90 beats/min in the month after ablation.24
Permanent atrial fibrillation
For permanent atrial fibrillation, the principal objec›
tive, other than effective anticoagulation to prevent
stroke, is control of heart rate. This can usually be
achieved with atrioventricular node blocking drugs.
When drugs are ineffective, poorly tolerated, or cause
symptomatic bradycardia, “ablate and pace” treatment
is indicated. Anticoagulation is required afterwards
because the atria continue to fibrillate and the risk of
systemic embolism persists.
Recognition that atrial fibrillation is maintained by
the presence of macro re›entry circuits, which occupy a
critical amount of space in the atria, has prompted the
development of treatments that prevent re›entry and
thus prevent atrial fibrillation. The aim of these
treatments is to create zones that block electrical
conduction to prevent the propagation of these
circuits. The surgical maze procedure is one such treat›
ment, and both the rate of successful treatment and the
rate of operative complication have driven the
development of catheters that can produce contiguous,
linear lesions that can compartmentalise the atria
without the need for surgery.14 Early results indicate
that linear ablation requires further refinement, but it
may have a future role in the management of
persistent and permanent atrial fibrillation.20
Which patients are suitable for ablation?
At present, radiofrequency ablation is not a first line
treatment for atrial fibrillation, but it should be consid›
ered for certain patients. For patients with paroxysmal
atrial fibrillation, focal ablation may be an option if
Fig 3 Radiograph showing catheters positioned within the heart for
focal pulmonary vein ablation. The tip of the catheter in the right
upper pulmonary vein is outside the cardiac silhouette
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antiarrhythmic drugs are ineffective or not tolerated.
Patients who have frequent atrial ectopic beats with a
consistent P wave morphology indicating a single
ectopic focus are most suited to focal ablation (fig 3).
This procedure is new and has not yet been adopted by
all regional electrophysiology centres.
For persistent and permanent atrial fibrillation,
ablation of the His bundle and implantation of a pace›
maker is a good option if satisfactory control of heart
rate cannot be achieved with atrioventricular node
blocking drugs, or if side effects occur. This procedure
can also be used for paroxysmal atrial fibrillation in
patients not suited to focal ablation. Although promis›
ing, linear ablation is still an experimental treatment
and requires further evaluation before it can be recom›
mended in clinical practice.
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Lesson of the week
Acute hyponatraemia in children admitted to hospital:
retrospective analysis of factors contributing to its
development and resolution
Michael Halberthal, Mitchell L Halperin, Desmond Bohn
Hyponatraemia (plasma sodium concentration less than
136 mmol/l) is acute if the decrease in natraemia occurs
within 48 hours. The major dangers from this are brain
cell swelling and herniation.1 2 Two factors are required
for hyponatraemia to develop: a source of electrolyte
free water and vasopressin to prevent the excretion of
that water.3 Electrolyte free water is given routinely as
maintenance fluids based on formulas developed in
studies in healthy children more than 40 years ago.4 5
There are many reasons to anticipate that vasopressin
will be released in sick patients (box).6 Patients with an
acute illness may arrive in hospital with a low plasma
sodium concentration because of previous water intake.
Hence, to minimise the potential threat of brainstem
herniation it is important to measure the plasma sodium
concentration if intravenous solutions are to be given.
We describe symptomatic hyponatraemia develop›
ing over 48 hours in children. In each patient,
hypotonic solutions were infused using current guide›
lines.7 We related the volume of electrolyte free water
given to the decrease in natraemia and assessed
whether actions of vasopressin persisted to guide
emergency corrective therapy.8
Causes of vasopressin release
• Hypernatraemia (most important stimulus, but not
in these patients)
• Low “effective” circulating volume (greater than 7%
decrease in extracellular fluid volume)
• Nausea, pain, anxiety
• Drugs (some act through inducing nausea)
• Afferent stimuli by way of the vagus nerve—for
example, lung lesions
• Disturbances of the central nervous system
(meningitis, encephalitis)
• Metabolic and endocrine disorders—for example,
hypothyroidism, hypoadrenalism, porphyria
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